The Revenge of a DES Son

See the 1983 Article Page 1 on Flickr

The story of a lawyer who used to defend DES-makers until he discovered his was a DES son
“The Revenge of a DES Son”, Page1

The fascinating and devastating story of a lawyer who used to defend DES-makers until he discovered his was a DES son. Page1 (to be continued)

Read Before His Cancer Ordeal, Lawyer Craig Diamond Defended Des-Makers: Now He’s Suing His Former Clients
by John Saar, 09 May 1983

Watch the Diaporama, and the DES media photo set on flickr®  DES Diethylstilbestrol's photostream on Flickr

If you already have a flickr® account, add us as a contact. Email your photos to des.daughter@gmail.com with a short description and title :-)

DES DiEthylStilbestrol Resources

Dépakine et grossesse: nos enfants empoisonnés!

Les anti-épileptiques, le Valproate de Sodium

Reportage 3013 RTL-TV sur le syndrome du valproate avec témoignage de membres de l’APESAC. La Dépakine, anti-épileptique très connu et très répandu dans les années 80, causerait des malformations sur les fœtus chez les femmes épileptiques et enceintes.

Les médicaments, en savoir plus:

Hormone Therapy may pose higher Breast Cancer Risk in some Women

The increase in risk varies depending on a woman’s race, body mass index and breast density

Hormone Therapy May Pose Higher Cancer Risk in Some Women
Hormone Therapy may pose higher Breast Cancer Risk in some Women

Taking hormones to treat the symptoms of menopause is thought to increase women’s risk of breast cancer, but this risk doesn’t rise equally in all women, a new study finds.

The researchers looked at nearly 1.65 million postmenopausal women ages 45 and older, and found that leaner women, as well as women with denser breasts, were more likely to see the detrimental effects of hormone replacement therapy (HRT) on their breast cancer risk.

Read Hormone Therapy May Pose Higher Cancer Risk in Some Women
by Bahar Gholipour, LiveScience, 03 Sept 2013.

Related post: HRT-use associated with an increased Risk of Breast Cancer, Research suggests.

Cole’s Pregnancy Fight diagnosed with Premature Ovarian Failure

Beating the Odds after being diagnosed with Premature Ovarian Failure

Beating the odds after being diagnosed with Premature Ovarian Failure
Personal stories

My name is Cole. I’m writing this today because I feel it is important to get my story out there to as many women as possible. To give inspiration to those wanting a family but are suffering from infertility and encourage them to not lose hope.
I am 34 years old and had come off of birth control last summer after seventeen years. When I didn’t get my period back after four months my OBGYN recommended I see a reproductive specialist.
Upon doing so I was given a battery of blood tests to measure my hormone levels. When the test results came back I was given the shock of my life. The numbers indicated I was POSTmenopausal with diminished ovarian reserve
. ”

Continue reading Beating the Odds after being diagnosed with Premature Ovarian Failure
on MyFertilityChoices.comPersonal Stories – follow on Twitter

Meet Cole on Blogger: One In Ten Million: My Fight to Get Pregnant Despite Premature Ovarian Failure

Breast Cancer Risk linked to Occupations with Exposure to Carcinogens and Endocrine Disruptors

Canadian case–control study, BioMed Central, Nov 2012

Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case–control study
@BioMedCentral : The Open Access Publisher

This Canadian case control study showed that women who work in certain occupations, most notably automotive plastics manufacturing and food packaging, have a higher risk of breast cancer as young women.

Background:
Endocrine disrupting chemicals and carcinogens, some of which may not yet have been classified as such, are present in many occupational environments and could increase breast cancer risk. Prior research has identified associations with breast cancer and work in agricultural and industrial settings. The purpose of this study was to further characterize possible links between breast cancer risk and occupation, particularly in farming and manufacturing, as well as to examine the impacts of early agricultural exposures, and exposure effects that are specific to the endocrine receptor status of tumours.

Methods:
1005 breast cancer cases referred by a regional cancer center and 1146 randomly-selected community controls provided detailed data including occupational and reproductive histories. All reported jobs were industry- and occupation-coded for the construction of cumulative exposure metrics representing likely exposure to carcinogens and endocrine disruptors. In a frequency-matched case–control design, exposure effects were estimated using conditional logistic regression.

Results:
Across all sectors, women in jobs with potentially high exposures to carcinogens and endocrine disruptors had elevated breast cancer risk (OR = 1.42; 95% CI, 1.18-1.73, for 10 years exposure duration). Specific sectors with elevated risk included: agriculture (OR = 1.36; 95% CI, 1.01-1.82); bars-gambling (OR = 2.28; 95% CI, 0.94-5.53); automotive plastics manufacturing (OR = 2.68; 95% CI, 1.47-4.88), food canning (OR = 2.35; 95% CI, 1.00-5.53), and metalworking (OR = 1.73; 95% CI, 1.02-2.92). Estrogen receptor status of tumors with elevated risk differed by occupational grouping. Premenopausal breast cancer risk was highest for automotive plastics (OR = 4.76; 95% CI, 1.58-14.4) and food canning (OR = 5.70; 95% CI, 1.03-31.5).

Conclusions:
These observations support hypotheses linking breast cancer risk and exposures likely to include carcinogens and endocrine disruptors, and demonstrate the value of detailed work histories in environmental and occupational epidemiology.

Sources Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case–control study, BioMed Central, Nov 2012 – full PDF

Related post: Higher Breast Cancer Risk for Women Workers exposed to Plastics Industry Endocrine Disruptors

Dépakine (Acide Valproïque Sanofi-Aventis) et anti-épileptiques: question à l’Assemblée Nationale

Ministère affaires sociales et santé, M. Jacques Cresta, 2013

Dépakine (laboratoire Sanofi-Aventis) et anti-épileptiques: une question à l'assemblée nationale
La Dépakine, un médicament anti-épileptique, a continué à être prescrite à de nombreuses femmes enceintes

Texte de la question:
M. Jacques Cresta attire l’attention de Mme la ministre des affaires sociales et de la santé sur les conséquences de l’acide valproïque sur le fœtus. Il a été diagnostiqué chez certains enfants le syndrome anti-convulsivant qui induit une multitude de handicaps, dont un trouble du comportement, ne permettant pas à ces derniers de suivre une scolarité normale. Ce syndrome aurait été inoculé par la mère épileptique, traitée durant leur grossesse par une molécule : l’acide valproïque. Cette molécule autrefois propriété du laboratoire Sanofi-Aventis et exploitée sous le nom commercial de Dépakine est ensuite tombé dans le domaine public et apparaîtrait désormais dans la composition de nombreux anti-épileptiques génériques. Malgré que les effets tératogènes aient été répertoriés dans le dictionnaire Vidal, faisant référence en la matière, cette molécule a continué à être prescrite à de nombreuses femmes enceintes. Il souhaiterait connaître la position du Gouvernement sur cette question et quelles sont les mesures qu’il compte prendre pour y mettre un terme.

Texte de la réponse:
Il convient de rappeler qu’en dehors de tout traitement médicamenteux, l’épilepsie elle-même peut être de nature, chez une femme enceinte, à générer des malformations chez l’enfant à naître. L’interruption brutale du traitement antiépileptique peut entraîner une aggravation de la maladie chez la mère, avec notamment le retour de crises épileptiques, qui peut s’avérer préjudiciable pour le foetus. Le valproate de sodium a montré une réelle efficacité pour équilibrer la maladie chez certains patients épileptiques pour lesquels les autres substances n’y parviennent pas. C’est pourquoi même en cas de survenue d’une grossesse, la poursuite du traitement par valproate peut s’avérer nécessaire. Malgré la toxicité potentielle de la substance pour le nouveau-né exposé in utero, la prescription du traitement chez la femme enceinte est autorisée dans les autorisations de mise sur le marché des spécialités à base de valproate de sodium dont Depakine® mais sous conditions et assortie de mesures d’encadrement. Le risque tératogène est mentionné dans le résumé des caractéristiques du produit (RCP) et dans la notice pour les patients de la spécialité Dépakine®. Sur ce point, il y a lieu de souligner que l’évolution des connaissances a conduit l’agence nationale de sécurité du médicament et des produits de santé (ANSM) à de régulières mises à jour des informations relatives aux risques et aux conditions de prescription portées tant à la connaissance des prescripteurs qu’à celle des patients. Ainsi le RCP du produit précise que lors de l’instauration d’un traitement chez une femme en âge de procréer, il convient de s’assurer que la patiente n’est pas enceinte et de lui prescrire une méthode de contraception efficace avant le début du traitement si nécessaire. Si une grossesse est envisagée chez une femme traitée par valproate de sodium, l’intérêt du traitement doit être réévalué, et toutes les mesures pour envisager le recours à d’autres thérapeutiques en vue de cette grossesse doivent être mises en oeuvre. Si le traitement doit absolument être maintenu pendant la grossesse du fait de l’absence d’alternative thérapeutique, il convient d’administrer la dose journalière minimale efficace sans dépasser 1000 mg/j, de privilégier la monothérapie et des formes à libération prolongée, ou à défaut de répartir la dose journalière minimale efficace en plusieurs prises afin d’éviter les pics plasmatiques de valproate de sodium. De plus, un dépistage des malformations doit être mis en place pour déceler l’éventuelle survenue d’anomalies. Ces informations sont également précisées dans la notice pour les patients. Par ailleurs, l’agence européenne du médicament (EMA) procède actuellement à l’évaluation à l’échelle européenne des effets du valproate de sodium sur le développement neurocomportemental des enfants exposés in utero.

Sources: Ministère affaires sociales et santé, Question N° : 16732 de M. Jacques Cresta, 29/01/2013 – PDF – via F.A.C.T.

Post similaire: L’exposition in-Utero au médicament antiépileptique #Valproate et effets sur le cerveau des fœtus

Les médicaments, en savoir plus:

The SGK1 Protein that could help treat Infertility and Miscarriage in Future

Could a ‘Fertility Switch’ Save Women From Pain Of Infertility Or Miscarriage?

'Fertility Switch' Could Save Women From Pain Of Infertility Or Miscarriage
Deregulated expression of SGK1 in the endometrium has been implicated in cases of infertility or recurrent miscarriage in humans, and SGK1 expression in the endometrium also affects fertility in mice

Scientists from the Imperial College London have discovered an enzyme in the body that determines infertility and the chances of miscarriage, as it acts like a ‘switch. The SGK1 protein discovery could pave the way for new treatments and/or be used before women undergo IVF…

Read ‘Fertility Switch’ Could Save Women From Pain Of Infertility Or Miscarriage, HuffPost Women, 17/10/11

Sadly for many DES daughters having their own children is not possible! Many of us who have experienced miscarriages, want to have kids but are struggling or unable to…

Find out more about DES pregnancy risks and read DES studies on fertility and pregnancy.

Birds, Fish, aquatic Life exposed to Drugs in Lake Michigan

Pharmaceuticals and personal care products found in the Great Lakes above concentrations of environmental concern

Drugs found in Lake Michigan, miles from sewage outfalls
Birds, fish and other aquatic life are exposed to drugs in Lake Michigan

Prescription drugs are contaminating Lake Michigan two miles from Milwaukee’s sewage outfalls, suggesting that the lake is not diluting the compounds as most scientists expected, according to new research. This ability of the drugs to travel and remain at relatively high concentrations means that fish and other aquatic life are exposed, so there could be “some serious near-shore impacts,” said Rebecca Klaper, an associate professor at the University of Wisconsin-Milwaukee. In addition, Milwaukee draws its drinking water from Lake Michigan, although no pharmaceuticals have been detected in the city’s water. The researchers reported that 14 of the chemicals “were found to be of medium or high ecological risk,” and that the concentrations “indicate a significant threat to the health of the Great Lakes” .

Read Drugs found in Lake Michigan, miles from sewage outfalls, by Brian Bienkowski, EHN, 5 Sept 2013

Sources Pharmaceuticals and personal care products found in the Great Lakes above concentrations of environmental concern, Science Direct, 23 Aug 2013 – PDF

Cervical Screening and general Physical Examination Behaviors of Women exposed to DES

One third of DES-exposed women are not receiving annual Pap smear examinations

DES Follow-up Study Summary

National Cancer Inst logo image
One third of DES-exposed women are not receiving annual Pap smear examinations.

In this study we evaluated whether women who were exposed in utero to Diethylstilbestrol (DES) follow the recommendations for cervical screening and general physical examinations.

DES-exposed (3140) and unexposed women (826) from the Houston, Boston, Rochester and Los Angeles sites reported on the 1994 questionnaire how frequently over the preceding five years (1990-1994) they had Papanicolau (Pap) smears and general physical examinations.

The study found that DES-exposed women exceeded the recommended frequency of Pap smear screenings compared to unexposed women. The DES exposed women also exceeded the annual recommendations for physical examinations among women without a history of chronic disease when compared to unexposed women. Whereas most DES-exposed women are receiving cervical cancer screening at recommended intervals, a third are not having these annual Pap smear examinations.

2008 Study Abstract

Objective:
To estimate whether women exposed in utero to diethylstilbestrol (DES) report receiving more cervical and general physical examinations compared to unexposed women.

Materials and Methods:
1994 Diethylstilbestrol Adenosis cohort data are used to assess the degree of recommended compliance of cervical screenings found in 3,140 DES-exposed and 826 unexposed women. Participants were enrolled at 4 sites: Houston, Boston, Rochester, and Los Angeles. Logistic regression modeling was used to analyze mailed questionnaire data, which included reported frequency over the preceding 5 years (1990-1994) of Papanicolaou smears and general physical examinations.

Results:
Diethylstilbestrol-exposed women exceeded the recommended frequency of Papanicolaou smear screenings [adjusted odds ratio (aOR) = 2.15, 95% CI (confidence interval) = 1.60-2.88] compared to the unexposed. This association held among those without a history of cervical intraepithelial neoplasia (aOR = 1.88, 95% CI = 1.35-2.62). Diethylstilbestrol-exposed women exceeded annual recommendations for physical examinations (aOR = 2.27, 95% CI = 1.16-4.43) among women without a history of chronic disease when compared to unexposed women.

Conclusions:
Most DES-exposed women are receiving cervical cancer screening at least at recommended intervals, but one third of the women are not receiving annual Papanicolaou smear examinations.

Sources

  • Cervical screening and general physical examination behaviors of women exposed in utero to diethylstilbestrolNCBI, PMID: 18369304, 2008 Apr;12(2):111-7. doi: 10.1097/LGT.0b013e31815ae980.
  • NCI, DES Follow-up Study Published Papers.
Related posts
More DES DiEthylStilbestrol Resources

Valproate Epilepsy Drug linked to increased Risk of having a Baby with Spina Bifida or Hypospadias

Epilepsy drug dosage linked to specific birth defects

Researchers discover link between epilepsy drug and risk of having baby with birth defects
Epilepsy experts at The Royal Melbourne Hospital discovered the link

According to new research, the medical journal of the American Academy of Neurology, epilepsy experts at The Royal Melbourne Hospital have discovered a link between high doses of common epilepsy drug valproate and the increased risk of having a baby with spina bifida or hypospadias.

Abstract

 

Objective
To study the relationships between maternal valproate dose in pregnancy and the pattern of various fetal malformations.
Methods
Analysis of data in the Australian Register of Antiepileptic Drugs in Pregnancy collected from 1999 to 2012. The specific type of fetal malformation in offspring exposed to valproate in utero was correlated with the dose of valproate taken by the mother in the first trimester.

Results
Compared with other malformations, the mean dose of valproate taken during the first trimester was higher in mothers whose offspring had spina bifida (2,000 ± 707 vs 1,257 ± 918 mg/d) and hypospadias (2,417 ± 1,320 vs 1,235 ± 715 mg/d) (both p < 0.05). The overall mean maternal valproate dosage taken by women in the Register decreased over the last 5 years of the study period. This was paralleled by a statistically significant decrease in the rate of occurrence of spina bifida and hypospadias, but not other malformations.

Conclusions
Human fetal malformations associated with valproate exposure during pregnancy do not all seem to bear the same quantitative relationship to drug dose, and reduction in valproate dose in earlier pregnancy is likely to offer greater dividends in protecting against spina bifida and hypospadias than against other types of fetal malformations.

Read Epilepsy drug dosage linked to specific birth defects,
26 Aug 2013.

Related post: Researchers discover link between epilepsy drug and risk of having baby with birth defects, News Medical, 26 Aug 2013.